You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Urine Diagnostics for Aspergillosis

    SBC: PEARL DIAGNOSTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Aspergillosis is a severe fungal infection that most frequently involves the lungs in people who have immune deficiency caused by cancer chemotherapy and or transplantation Although good drugs are available establishing a diagnosis is difficult and late treatment has limited our progress in decreasing morbidity and mortality We observed that Aspergillus pol ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Rapid Diagnostics for Mucormycosis

    SBC: VITALEX BIOSCIENCES LLC            Topic: NIAID

    DESCRIPTION provided by applicant Mucormycosis most commonly caused by Rhizopus oryzae is a life threatening infection that occurs in patients immunocompromised by diabetic ketoacidosis DKA neutropenia corticosteroid use and or increased serum iron Because of the rising prevalence of these risk factors the incidence of mucormycosis has risen Despite disfiguring surgery and aggressive ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Developing efficient and safe cell-permeable reprogramming peptides for generation of iPS cells.

    SBC: Vivoscript, Inc.            Topic: 200

    DESCRIPTION provided by applicant The groundbreaking discovery of induced pluripotent stem cells iPSCs has opened a new page for developing personalized cell based therapies against various devastating human diseases without ethical concerns of using human embryonic stem cells However the future clinical applications of iPSCs remain in doubt due to potential risks of undesired genomic alter ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as biosafety level agents Currently there is no effective vaccine or therapeutic treatment against f ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Optimizing HaploSeq for whole-genome phased haplotypes in biomedical applications

    SBC: ARIMA GENOMICS, INC.            Topic: 172

    DESCRIPTION provided by applicant Phenomenal advances in DNA sequencing technologies have enabled systematic identification of genetic variants in human individuals and the recent FDA marketing authorization of the first next generation genome sequencer signals the arrival of a new era of pharmacogenomics and personalized medicine Nevertheless DNA sequencing alone fails to provide complete i ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Therapeutics to Treat Candida albicans Biofilm Infections

    SBC: BIOSYNESIS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The yeast Candida albicans is a normal resident of the human digestive tract It is also the most common fungal pathogen of humans causing both mucosal and systemic infections particularly in immune compromised individuals The majority of new C albicans infections arise from the presence of persistent C albicans cells existing in a biofilm These biofilm b ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Enhancing Care of the Aged and Dying in Prisons

    SBC: KLEIN BUENDEL, INC.            Topic: NIA

    DESCRIPTION provided by applicant The United States has the highest rate of incarceration in the world The demographics of the prison population are shifting In fact the number of sentenced state and federal prisoners age or older grew at times the rate of the overall prison population from The health status of aging inmates does not mirror the free world population In fac ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Breath ammonia monitoring device for children with urea cycle disorders

    SBC: Lumina Diagnostics, Inc.            Topic: NICHD

    DESCRIPTION provided by applicant We propose to develop a non invasive device to enable children with urea cycle disorders and their parents guardians and physicians to actively manage the disorder at home and improve outcomes in the clinic Urea cycle disorders UCD are inborn errors of metabolism that impair oneandapos s ability to convert ammonia NH a neurotoxin into urea which is ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. USE OF DNATrax TO MODEL THE TRANSPORT OF PARTICULATE MATTER IN URBAN ENVIRONMENTS

    SBC: DNATREK, LLC            Topic: NIEHS

    DESCRIPTION provided by applicant Science based strategies for quantifying and mitigating the impact of anthropogenic emissions on public health are essential for the sustainability of cities Similar strategies can also be used to develop and assess the effectiveness of a national defense system against terrorist attacks with airborne biological agents and protect against the spread of airborn ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemia

    SBC: MICROFLUIDIC INNOVATIONS, LLC            Topic: 102

    DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government